IMARC Group, a leading market research company, has recently releases report titled “Pharmaceutical Continuous Manufacturing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028.” The study provides a detailed analysis of the industry, including the global pharmaceutical continuous manufacturing market size, growth, share, trends, and forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
How Big Is the Pharmaceutical Continuous Manufacturing Market?
The global pharmaceutical continuous manufacturing market size reached a value of US$ 1.2 Billion in 2022. It is projected to reach a value of US$ 2.3 Billion by 2028, exhibiting a CAGR of 11.6% during 2023-2028.
What is Pharmaceutical Continuous Manufacturing?
Pharmaceutical continuous manufacturing is an innovative approach to drug production that differs from traditional batch manufacturing. It can lead to reduced production times, lower energy consumption, and reduced waste generation. It allows for constant monitoring and control of various parameters throughout the production process, which can result in better quality control and the ability to detect and address issues promptly and leads to higher product quality and consistency. It also enables precise control of reaction conditions and can lead to higher yields and purities.
Pharmaceutical Continuous Manufacturing Market Trends and Drivers:
The increasing requirement for effective medicine production systems for composing different effective biologics at a lower cost represents one of the key factors driving the demand for pharmaceutical continuous manufacturing around the world. Moreover, the rising demand for pharmaceuticals and vaccines, particularly with the ongoing global health challenges, and the surging prevalence of several chronic diseases among the masses are favoring the growth of the market. Additionally, the integration of process analytical technology (PAT) for more reliable and efficient pharmaceutical continuous manufacturing is contributing to the market growth. Apart from this, measures undertaken by regulatory agencies to encourage pharmaceutical companies to adopt continuous manufacturing practices as they can help enhance product quality and offer real time monitoring of the production process is bolstering the market growth.
What Is Included in Market Segmentation?
The report has segmented the market into the following categories:
Breakup by Therapeutics Type:
- Large Molecules
- Small Molecules
Breakup by Formulation:
- Solid Formulation
- Liquid and Semi-solid Formulation
Breakup by Application:
- Final Drug Product Manufacturing
- API Manufacturing
Breakup by End User:
- Pharmaceutical Companies
- Contract Manufacturing Organizations
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Who Are the Key Players Operating In The Industry?
Top Key Players covered in this report are: Baker Perkins, Coperion GmbH (Hillenbrand Inc.), Eli Lilly and Company, GEA Group Aktiengesellschaft, Glatt GmbH, Korsch AG, Novartis AG, Siemens, SK biotek, Thermo Fisher Scientific Inc. and Viatris Inc.
Comments
0 comment